Background: Prompt evaluation and appropriate treatment with wide-spectrum antibiotics is considered mandatory for febrile oncology patients especially during neutropenia. Central venous catheters are widely used in pediatric oncology patients and are often the source of infections. Patients are usually admitted for follow-up and administration of antibiotics. Aims were to assess the efficacy of the polymerase chain reaction (PCR) method in identifying bacteria in blood samples as compared with standard blood cultures.
F ever is common in cancer patients. Prompt evaluation and appropriate treatment with wide-spectrum antibiotics is considered mandatory, especially for patients with fever and neutropenia. 1 Management of fever without neutropenia in a pediatric hematology-oncology setting is less clear, although there are guidelines regarding the treatment of patients with central venous catheters (CVC). 2 The risk of infection associated with subcutaneously implanted central venous access devices (SICVAD) in pediatric patients with cancer is considered low. Blood cultures may be positive in 20% to 30% of patients in the setting of fever and neutropenia. 1, 3, 4 Prior use of antibiotics, infection with fastidious organisms, and other factors may hamper the potential for isolating pathogens in blood cultures. 5, 6 In addition, the emergence of resistant pathogens renders empirical treatment much more difficult in the setting of severe immunosupression. Early detection of patients with blood stream infection (BSI) may help to target these life-threatening situations with appropriate antibiotics.
Eubacterial 16S rRNA gene amplification with polymerase chain reaction (PCR) uses primers that are complementary with sequences conserved in all bacteria and allows early detection of pathogens, including those not culturable. 7 Recent studies have shown that this method may detect bacterial and fungal BSI, even in culturenegative samples. 6, [8] [9] [10] [11] We aimed to evaluate the potential role of molecularbased diagnosis in the rapid detection of BSI among febrile oncologic patients in our hematology-oncology department.
SETTING
Our Pediatric Hematology-Oncology Department is a tertiary medical center with 40 beds and an annual intake of 90 to 100 newly diagnosed children, including 20 to 30 bone marrow transplant patients per year.
METHODS
A prospective, noninterventional study was conducted over a 15-month period (September 2004 to November 2005). All patients with fever were treated in the hospital. Clinical and epidemiological parameters were collected, and blood cultures were taken for each episode of fever with or without neutropenia. The study was approved by the local ethical board committee.
Blood Culture Samples
Blood (4 mL) was drawn for blood culture and PCR amplification of bacterial 16 S rRNA gene from permanent CVCs and peripheral veins (where possible) according to the local protocol for the management of fever (>38.21C) with or without neutropenia was carried out. Three milliliters of blood was inoculated into pediatric blood culture bottles that were processed using the automated continuous-monitoring blood culture system (BACTEC 9240 blood culture system; Becton Dickinson Diagnostic Instruments Systems, Sparks, MD) according to the standard microbiological protocols.
16S rRNA Gene PCR Amplification
One milliliter of blood was collected in an EDTAcontaining tube for PCR analysis. DNA was extracted from 200 mL of blood using a commercial kit (QIAamp DNA Mini Kit; QIAGEN, Westburg, Israel) according to the manufacturer's instructions. The 16S rRNA gene was PCRamplified using primer pairs as previously described. 9 Identification of DNA amplification products was performed by electrophoresis on 1.5% agarose gel. PCR results were available within 6 hours. Each PCR reaction included 4 controls: 1 negative control sample controlling for PCR contamination when water was substituted for the DNA sample; a second negative control sample, controlling for contamination during DNA extraction when a blank sample was processed in parallel with the patient sample; an inhibition control for each sample; and a positive control sample consisting of bacterial DNA. Altogether, these 4 control samples ensured the reliability of the PCR reaction. Resulting amplicons were directly sequenced using the BigDye terminator sequencing system on an ABI Prism 3100 sequencer (PE Applied Biosystems). Sequence identity was determined using the Blast analysis software (Blast; http://www.ncbi.nlm.gov/Blast). Percent identity score of 97% and 99% were used to classify microorganisms according to genus and species, respectively.
Statistical Methods
Specificity and sensitivity, positive predictive value, and negative predictive value were calculated, comparing standard blood cultures and PCR results.
RESULTS
A total of 115 episodes of new onset fever were documented, of which 148 pairs of blood samples were collected for culture and PCR. Blood cultures were positive in 21 (18.3%) episodes, 3/11 (27.3%) in patients <1 year old, 4/24 (16.7%) in patients 1 to 5 years old, and 14/80 (17.7%) in patients >5 years old.
Bacteremia was detected in 24.2% of the febrile episodes among children with tunneled catheters (Hickman or Broviac) as compared with 9.1% in patients with a Port-ACath (P = 0.046). BSI was detected in 10/51 (19.6%) patients with hematological malignancies and 5/54 (9.3%) patients with solid tumors. In 13/55 (23.6%) episodes of fever, bacteremia was identified in patients after bone marrow transplantation.
Molecular-based Diagnosis
We evaluated 148 paired samples (standard blood culture and PCR) ( Table 1 ). More than one set was available for some patients. In 26/148 (17.6%) samples, a single pathogen was isolated; concordance between standard blood culture and PCR results is presented in Table 2. PCR sensitivity, specificity, and positive and negative predictive values were 46%, 98%, 86%, and 89% respectively, as compared with standard blood cultures.
DISCUSSION
Infections in children treated for cancer are common, may be associated with neutropenia or the existence of CVC, and have significant effects on mortality and morbidity. 1, 12 Patients with fever and neutropenia are promptly treated with broad-spectrum antibiotics, regardless of the result of blood culture. 1 Pediatric patients treated for cancer are usually managed by implantable CVC. These patients may develop bacteremia, even without neutropenia, mainly attributed to the existence of an endovascular foreign body. Published articles focus on febrile patients with neutropenia, mainly because of the hazardous results of BSI in this setting and the morbidity and mortality that can result from those events. Bacteremia is detected in 10% to 35% of febrile neutropenic children, 1, 3, 4 whereas infectious complications of SICVAD in children are considered low. 5 Therapeutic decisions should ideally be based on microbial isolation and susceptibility patterns, especially in the era of resistant pathogens. Early appropriate empirical antibiotic therapy may be crucial for children treated for cancer, as in the case of sepsis and bacteremia. [12] [13] [14] Our policy is to start initial empiric therapy for febrile children This may expose a significant number of children to multiple courses of antibiotics along with their side effects and the potential for emergence of resistance due to the widespread use of antibiotic therapy.
Our study aimed at evaluating the potential usefulness of PCR for the detection of microbial DNA before initiation of empiric therapy without considering the clinical significance of the identified pathogen. Bacteremia was more common among patients treated with Hickman or Broviac as compared with a Port-A-Cath as described elsewhere. 15, 16 The PCR method has been increasingly employed for the early detection of bacteremia in high-risk patients [17] [18] [19] [20] [21] with variable sensitivity. In our study, 148 paired samples were tested. Although the sensitivity of the test remained below a satisfactory level, the specificity was very high (98%), correctly identifying blood culture isolates. Another obstacle of the PCR technique, apart from the low sensitivity, is the fact that susceptibility testing cannot be performed (unless resistance is also being assessed by the molecular technique). We performed the test on fresh blood samples with no incubation period. The low sensitivity of the test may be explained by the small inoculum size or other blood factors that may prevent the progression of PCR reaction. 12 The low sensitivity of PCR in blood samples may be improved by overcoming the inhibitory effects attributed to some blood components 22 and combining PCR methods with other methods of microarray, thereby increasing the sensitivity and specificity. 23 Most of the negative isolates by blood culture were negative by PCR as well, yet PCR identified pathogens that had not been identified by culture in 2 cases. This may imply some role for this technology in identifying unusual pathogens. The first case was anaerobic bacteria (Fusobacterium nucleatum), which can be missed in a regular blood culture, and the second was Roseateles, which may not have a clinical role. Another point for PCR identification is the ability to recognize fastidious or slow-growing organisms, as in the case of atypical mycobacteria. If the technique can identify those pathogens early, treatment and line removal may be carried out immediately.
Although the incidence of resistant bacteria in our hospital is very low, when considering the emergence of resistance and the low probability of identifying the appropriate empirical therapy for the patient, especially when treatment for the pathogen is not included in the empirical therapy (eg, Stenotrophomonas, vancomycinresistant Enterococcus, etc.), early recognition and detection of those pathogens is crucial. We believe that the PCR method for identifying bacteria in the blood, with its early identification and ability to recognize slow or difficult to grow pathogens, can add value to blood culture results; it cannot, however, replace blood cultures, at least in the near future, until more technical obstacles are addressed.
In conclusion, our study has shown that febrile children treated with chemotherapy have a significant rate of bacteremia, whether neutropenic or not. This implies that these patients should be treated with a broad-spectrum combination antibiotic suitable for both gram-positive and gram-negative bacteria. Applying the technology of 16S RNA PCR on a fresh sample of blood has a high specificity and may even identify a subset of fastidious pathogens within 4 to 6 hours. The sensitivity of this method needs further improvement. More studies are needed in this field, especially among pediatric and high-risk patients.
